ArticleBMC cancer2021
Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.
Khine Kyaw Oo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this papercites it